Published 14 hours ago • loading... • Updated 3 hours ago

Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype

Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

cancernetwork.com

Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype

Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.

3 hours ago

Read Full Article

targetedonc.com

RAMP 201 Data Shows Advancements in Recurrent Low-Grade Serous Ovarian Cancer

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

9 hours ago

Read Full Article

Clinical Trials Arena

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial

Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31%The post Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial appeared first on Clinical Trials Arena.

14 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year